Craft

Hybribio

Stock Price

¥6.3

2024-10-29

Market Capitalization

¥3.8 B

2024-10-29

Revenue

¥647.3 M

FY, 2025

Hybribio Summary

Company Summary

Overview
Hybribio (广东凯普生物科技股份有限公) is a manufacturer and supplier of nucleic acid molecular diagnostic products. It offers respiratory virus, human papillomavirus infection (HPV), hearing loss susceptibility genoarray diagnostic, and genotyping real-time polymerase chain reaction (PCR) kits, nucleic acid extraction and fluorescent quantitative detection systems, etc.
Type
Public
Status
Active
Founded
2003
Website
https://www.hybribio.cn
Cybersecurity rating
Sectors

Table of Contents

Hybribio Financials

Summary Financials

Revenue (Q1, 2026)
¥123.2M
Gross profit (Q1, 2026)
¥52.3M
Net income (Q1, 2026)
(¥6.4M)
Cash (Q1, 2026)
¥768.4M
EBIT (Q1, 2026)
(¥25.3M)
Enterprise value
$3.1B

Footer menu